Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) Director Mona Ashiya sold 10,011 shares of the company's stock in a transaction on Friday, March 21st. The stock was sold at an average price of $54.00, for a total value of $540,594.00. Following the sale, the director now owns 187,297 shares of the company's stock, valued at $10,114,038. This trade represents a 5.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Mona Ashiya also recently made the following trade(s):
- On Wednesday, March 19th, Mona Ashiya sold 39,656 shares of Disc Medicine stock. The stock was sold at an average price of $54.02, for a total transaction of $2,142,217.12.
- On Wednesday, March 12th, Mona Ashiya sold 83,182 shares of Disc Medicine stock. The shares were sold at an average price of $54.45, for a total transaction of $4,529,259.90.
- On Monday, March 10th, Mona Ashiya sold 202,146 shares of Disc Medicine stock. The stock was sold at an average price of $54.29, for a total transaction of $10,974,506.34.
Disc Medicine Price Performance
NASDAQ:IRON traded down $0.91 during midday trading on Tuesday, hitting $52.79. The company's stock had a trading volume of 182,245 shares, compared to its average volume of 360,626. Disc Medicine, Inc. has a fifty-two week low of $25.60 and a fifty-two week high of $68.73. The firm's 50 day moving average is $55.06 and its 200-day moving average is $56.15. The firm has a market cap of $1.82 billion, a P/E ratio of -13.26 and a beta of 0.73.
Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.08. As a group, analysts forecast that Disc Medicine, Inc. will post -4.07 EPS for the current year.
Hedge Funds Weigh In On Disc Medicine
A number of institutional investors have recently modified their holdings of the stock. Sterling Capital Management LLC boosted its stake in shares of Disc Medicine by 798.4% in the fourth quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock worth $36,000 after buying an additional 503 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Disc Medicine in the fourth quarter valued at approximately $40,000. Tower Research Capital LLC TRC boosted its position in Disc Medicine by 47.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock worth $52,000 after purchasing an additional 266 shares in the last quarter. Quest Partners LLC acquired a new stake in shares of Disc Medicine during the 3rd quarter worth approximately $131,000. Finally, Quantbot Technologies LP purchased a new position in shares of Disc Medicine during the 3rd quarter valued at approximately $146,000. Hedge funds and other institutional investors own 83.70% of the company's stock.
Analyst Upgrades and Downgrades
Several equities analysts have issued reports on the stock. TD Cowen started coverage on shares of Disc Medicine in a report on Thursday, February 27th. They issued a "buy" rating on the stock. Wedbush restated an "outperform" rating and set a $90.00 target price (up from $83.00) on shares of Disc Medicine in a research note on Tuesday, January 21st. HC Wainwright reaffirmed a "buy" rating and set a $118.00 target price on shares of Disc Medicine in a research report on Tuesday, January 21st. Stifel Nicolaus raised their price target on Disc Medicine from $90.00 to $94.00 and gave the stock a "buy" rating in a report on Friday, January 24th. Finally, Morgan Stanley restated an "overweight" rating and set a $85.00 price objective on shares of Disc Medicine in a report on Friday, March 7th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $93.80.
Check Out Our Latest Research Report on Disc Medicine
Disc Medicine Company Profile
(
Get Free Report)
Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Further Reading
Before you consider Disc Medicine, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Disc Medicine wasn't on the list.
While Disc Medicine currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
